1. The PPAR Journey: What Can We Expect in the Future?

2. Targets of Glucose-Lowering Drugs

3. PPAR-a and PPAR-g Agonists: Target Systems

4. Effects of Fibrates on Cardiovascular Events: A Systematic Review and Meta-Analysis

5. CV Events With PPAR-g Agonists

6. Expected Targets for Dual PPAR-a/g Agonists

7. Dual PPAR a/g Agonists

8. GALLANT 8: Effect of Tesaglitazar on Top of Metformin vs Metformin Alone on HbA1c

9. GLAD: Effect of Tesaglitazar vs Pioglitazone on Lipid Measures

10. Tesaglitazar: Effect on Serum Creatinine and Glomerular Filtration

11. Dual a/g PPAR Agonist: Effect of Muraglitazar on Metabolic Parameters

12. Effect of Muraglitazar on CV Outcomes

13. SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in T2D

14. SYNCHRONY: Cardiovascular Safety

15. SYNCHRONY: Effect of Aleglitazar on Markers of Renal Function

16. SESTA R: Impact of Supratherapeutic Doses of Aleglitazar on Renal Function in T2D

17. ALENEPHRO: Objective and Study Design

18. Summary: PPAR Therapy

19. Abbreviations

20. Abbreviations (cont)

21. References

22. References (cont)

23. References (cont)

24. References (cont)